Penthrox approved in The Netherlands and Bosnia & Herzegovina
5 May 2020 ASX Announcement Penthrox approved in The Netherlands and Bosnia & Herzegovina. Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for sale in The Netherlands and Bosnia & Herzegovina. The Marketing Authorisation issued by the Medicines Evaluation Board of the Netherlands and the Agency for Medicinal […]
Read morePenthrox is approved in Thailand
28 April 2020 ASX Announcement Penthrox is approved in Thailand Medical Developments International Limited (ASX: MVP), announce today that Penthrox® has been granted Market Authorisation in the Kingdom of Thailand. The Marketing Authorisation issued by the Thailand Food and Drug Administration (TFDA), is for Penthrox® to be used for Emergency relief of moderate to severe […]
Read moreFY20 Half Year Report and Accounts
19 February 2020 ASX ANNOUNCEMENT MVP has today released its FY20 Half Year Report and Accounts. Please refer to the following link for a copy – MVP FY20 Half Year Report
Read morePenthrox Marketing Authorisation Application in Russia
6 December 2019 ASX ANNOUNCEMENT Penthrox Marketing Authorisation Application in Russia Medical Developments International Limited (ASX: MVP) announced today that the Russian Ministry of Health has accepted MVP’s Marketing Authorisation Application (MAA) for review. MVP submitted the MAA for Penthrox on 30 September and after a two-month validation period, the Russian Ministry of Health advised […]
Read morePenthrox IND approved in China
21 November 2019 ASX ANNOUNCEMENT Penthrox IND approved in China Medical Developments International Limited (ASX: MVP) is delighted to announce the Chinese National Medical Product Administration (NMPA) has approved the opening of MVP?s Investigative New Drug (IND) application.? This application is a critical step and building block to having Penthrox approved for sale in China. […]
Read moreMVP signs new Manufacturing Development Project with CSIRO
29 October 2019 ASX ANNOUNCEMENT MVP signs new Manufacturing Development Project with CSIRO Medical Developments International Limited (ASX: MVP) is delighted to announce it has signed an extension to the 2017 agreement with Australia?s national science agency, the Commonwealth Scientific and Industrial Research Organisation (CSIRO), to develop new manufacturing technologies for pharmaceutical products. This agreement […]
Read morePenthrox approved in EUSEM guidelines
24 October 2019 ASX Announcement Penthrox® entered in the European Society of Emergency Medicine (EUSEM) guidelines as now being recommended and approved as first-line of treatment trauma medication. Medical Developments International Ltd (ASX: MVP) is delighted to announce that Penthrox has been included in the new EUSEM guidelines for the Management of acute pain in emergency […]
Read morePenthrox is launched in Italy
23 October 2019 ASX Announcement Penthrox? is launched in Italy Medical Developments International Ltd (ASX: MVP) is delighted to announce that Penthrox has been launched in Italy. MVP CEO Mr. John Sharman said, ?We are delighted to finally launch Penthrox in the important European market of Italy.? There has been a number of clinical studies […]
Read morePositive study results for Penthrox in Europe
22 October 2019 ASX Announcement Positive study results for Penthrox? demonstrating superiority over Standard of Care for acute trauma pain treatments in patients across Europe Medical Developments International Limited (ASX: MVP) is delighted to announce that data across 11 abstracts of studies conducted throughout Europe and presented at the EUSEM Congress on October 12th to […]
Read morePreliminary Final Report and Full Year Accounts
21 August 2019 ASX Announcement Preliminary Final Report and Full Year Accounts For the full report please click on the following link:?Preliminary Final Report and Full Year Accounts
Read more